A Study of the Presillion Stent in de Novo Coronary Lesions

Inclusion Criteria: * The patient must be \>= 18 years of age. * Patient is eligible for percutaneous coronary intervention (PCI). * Acceptable candidate for coronary artery bypass surgery (CABG). * Female patients of childbearing potential must have a negative pregnancy test within 7 days prior to enrolment and utilize reliable birth control for trial duration. * Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) or unstable angina pectoris (Braunwald Classification B\&C, I-II-III) or patients with documented silent ischemia. * Treatment of up to two de novo native coronary artery lesions in a maximum of two major coronary arteries. * Target reference vessel diameter of both lesions must be \>= 2.5mm and \<= 4.0mm in diameter (visual estimate). * Target lesion length must be \<= 30mm and be covered by one study stent. * Target lesion stenosis for both lesions is \> 50% and \< 100% (visual estimate). * At least TIMI I coronary flow. * Patient is willing to comply with the specified follow-up evaluation. * Patient must provide written informed consent prior to the procedure using a form that is approved by the local Ethics Committee. Exclusion Criteria: * Recent myocardial infarction (either STEMI or non STEMI \< 48 hours prior to planned index procedure). * The patient has unstable angina classified as Braunwald A I-II-III. * The patient has unprotected left main coronary artery disease (stenosis \>50%). * A significant (\> 50%) stenosis proximal or distal to the target lesion. * Angiographic evidence of thrombus within the target lesion. * Heavily calcified lesion and/or calcified lesion, which cannot be successfully predilated and/or an excessively tortuous vessel which makes it unsuitable for stent delivery and deployment. * Left ventricular ejection fraction \<= 25%. * Totally occluded lesion (TIMI 0 level). * The patient has impaired renal function (creatinine 3.0mg/dL) at the time of treatment. * The patient had a Cerebrovascular Accident (CVA) within the past 6 months. * Prior stent within 10mm of target lesion. * The target lesion is ostial in location (within 3.0mm of vessel origin). * The target lesion involves a bifurcation with a diseased (\>50% stenotic) branch vessel \>= 2.0mm in diameter (or side branch requiring intervention of protection). * The target lesion is located in a bypass graft. Note: stenting of lesions in bypassed native coronary arteries is allowed. * Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix ®) and ticlopidine (Ticlid ®), heparin, cobalt chromium, contrast agent (that cannot be managed medically). * The patient has any significant medical condition which in the investigator's opinion may interfere with the patient's optimal participation in the study. * The patient is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the study endpoints. * Intervention of another lesion within 30 days prior to, or is planned or highly probably to be performed 30 days after the index procedure.